Shantha Bio, PATH to Develop Rotavirus Vaccine (India)
This article was originally published in PharmAsia News
Executive Summary
Shantha Biotechnics in India is developing a multivalent vaccine against rotavirus as part of a partnership with PATH, the global nonprofit health organization, and the National Institutes of Health. The parties are pursuing the accelerated development of a new vaccine that is safe, effective, and affordable. Licensed vaccines for rotavirus include Merck's RotaTeq and GSK's Rotatrix, but they are not available in the country at present. Shantha will be using technology licensed from the United States. The completion of preclinical toxicology studies will be followed by clinical trials in 2008. (Click here for more